Abivax’s ABX464 enticing in theory for Covid-19 but mechanism, trial design issues belie potential for success
Focus:
-
![tezepelumab]()
AstraZeneca/Amgen’s Phase III tezepelumab potential to expand to noneosinopilic asthma patients backed by early data and MOA but caution remains
-
![Clinical trials disruption]()
Clinical trials disruption due to Covid-19 has begun to decline
-
![veklury]()
Gilead’s Veklury in Covid-19 treatment may miss full hospital coverage, with potential updates to pick up additional cost
-
![covid-19 clinical trials]()
More clinical trials disrupted due to Covid-19 begin to resume
-
![Rinvoq]()
Results of AbbVie’s Rinvoq in atopic dermatitis position it to rival Regeneron’s Dupixent
-
![mRNA-1273]()
Positive interim results from Moderna’s lead Covid-19 candidate mRNA-1273
Most Read
- Celltrion implements Veeva Vault eTMF to improve visibility into clinical trial activities
- Parexel launches integrated FPS model to drive delivery of clinical research partnerships
- Medable unveils telemedicine solution only for clinical trials
- Broader inclusion criteria to double eligible cancer patients for clinical trials, finds study
- Find out how pharma is fighting respiratory illnesses in the latest Pharma Technology Focus
Company A-Z
Latest Content
UK firm Almac Clinical unveils virtual auditing solution
UK-based contract development and manufacturing company Almac Group’s unit Almac Clinical Services has announced that it had digitised its on-site auditing process and unveiled a virtual auditing solution for global clients.
Kognitic Analysts Closely Monitoring Covid-19 Impact
Our analysts are closely monitoring the impact of Covid-19 on the oncology landscape, and the following infographics break down the oncology clinical trials, which have been terminated or suspended due to Covid-19.
Following positive Phase IIb data, Shield Therapeutics aims to initiate Phase III study for phosphate binder PT20 by 2022
Earlier this month, Phase IIb results were published for Shield Therapeutics’ PT20 (ferric iron oxide adipate), an oral iron-based phosphate binder, for the treatment of hyperphosphatemia (HPT) in dialysis-dependent chronic kidney disease (CKD) patients.
PLANSUN
Plansun capsules have been developed with specific ingredients to help promote and maintain health and even tanned skin.
Latest News
Close
Close
Close
Go Top